Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i

Dummer, Reinhard and Lebbé, Celeste and Atkinson, Victoria and Mandalà, Mario and Nathan, Paul and Arance, Ana and Richtig, Erika and Yamazaki, Naoya and Robert, Caroline and Schadendorf, Dirk and Tawbi, Hussein A. and Ascierto, Paolo A. and Ribas, Antoni and Flaherty, Keith and Pakhle, Neha and Campbell, Katie and Gusenleitner, Daniel and Masood, Aisha and Brase, Jan Christoph and Gasal, Eduard and Long, Georgina V. (2020) Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i. Nature medicine, 26 (9).

Abstract

While recent 5-year analyses of Phase III trials in metastatic melanoma have demonstrated that checkpoint inhibitors and targeted therapy lead to long-term survival, many patients experience progression and novel treatment strategies are needed. In parts 1 and 2 of COMBI-i (NCT02967692), spartalizumab + dabrafenib + trametinib demonstrated an objective response rate of 78% (95% CI, 61%-90%) and a complete response rate of 44%. Additionally, exploratory biomarker identified baseline biomarkers as well as on-treatment modulations that may predict patients likely to achieve long-term benefit.

Item Type: Article
Date Deposited: 21 Oct 2020 00:45
Last Modified: 21 Oct 2020 00:45
URI: https://oak.novartis.com/id/eprint/42164

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.